Background Amiodarone hydrochlor-
groups). There were no differences in the results offorced spirometry or static lung volumes between the two groups, or in the fall in A-aDo2 from rest to exercise. There was a small difference between the amiodarone and the control group in transfer factor for carbon monoxide corrected for lung volume (Kco 1P67 (0 3) and 1-83 (0-3) mmol min-' kPa-' 1`respectively) and in exercise capacity (140 (25) and 120 (30) w). Only three patients showed lung function impairment consistent with pneumonitis. No relation between lung function measures and cumulative doses of amiodarone or desethylamiodarone was found. Conclusions The prevalence of clinically evident pulmonary side effects was 4*9%, which is lower than that reported in studies in which higher daily maintenance doses ofamiodarone were given. The slightly lower Kco values and lower work load achieved by the patients taking amiodarone suggest a small effect of amiodarone in doses of 400 mg on lung function. A role for individual susceptibility to pulmonary complications of amiodarone treatment is suggested.
Amiodarone hydrochloride is a benzofurane derivative that was used widely as a coronary vasodilator in Europe from 1967 to the late 1970s.' It started to be used as an experimental antiarrhythmic agent in the United States in the early 1980s,2 and is effective in 75-80% of cases of supraventricular and ventricular arrhythmia refractory to standard antiarrhythmic agents.' The effectiveness of amiodarone is, however, offset by various side effects that limit its long term therapeutic use. Most prominent among these are cutaneous and neurological manifestations, thyroid dysfunction, hepatotoxicity, muscle weakness, ocular disturbances, and pulmonary complications.5
Interstitial pneumonitis associated with amiodarone was first reported by Rotmensch in 19806 and is often its most serious side effect.5~"" Several aspects of amiodarone lung toxicity are still controversial-namely, its prevalence (which has ranged from 1 to 20%1012) and the precise pathophysiological mechanism, which remains poorly understood."" Routine monitoring of pulmonary function, particularly single breath transfer factor for carbon monoxide (TLCO), has been recommended for early detection ofpulmonary complications by Kudenchuk and associates.'0 Their results have not, however, been reproduced in other series.81112
The present cross sectional study was specifically aimed to assess pulmonary side effects of amiodarone in patients with coronary disease having long term treatment with the drug. Special care was taken in selecting the sample populiation and in the protocol design to ensure compliance with treatment and to avoid any confounding effect of subclinical cardiac failure or smoking habit on pulmonary function.
Methods

POPULATION STUDIED
The original sample consisted of 61 subjects who had received amiodarone for a cardiac arrhythmia; 46 of them had been treated with amiodarone for at least one year and these were matched with a control group of 46 subjects. blurred vision in two; a morning sensation of sand in the eye in three; muscle weakness in two; and fine distal tremor in one. There were no gastrointestinal symptoms or clinical signs of thyroid disturbance. Amiodarone treated patients had higher plasma levels of thyroxine and reverse tri-iodothyronine than the control group (thyroxine 8 7 (3 3) v 6-2 (1 -8) ug/100 ml; p < 0-001; reverse tri-iodothyronine 388 (155) v 167 (1-8) pg/ml; p < 0-0001), findings consistent with enzymatic inhibition of the peripheral conversion of thyroxine to triiodothyronine by amiodarone.'6 Only three of the 61 patients fulfilled the criteria of possible pneumonitis as defined under "Methods" (table 1). One of the three had a recent history of dyspnoea on mild exercise, dry cough, and muscle weakness, and had a right pleural rub; another had bilateral crackles. The chest radiograph in two patients showed an interstitial infiltrate and the third showed a peripheral alveolar infiltrate. All three patients had arterial hypoxaemia at rest (table 1) and two had a reduction in static lung volumes and TLCO. All improved after amiodarone withdrawal. Two were also treated with oral prednisone (initial dose 1 mg/kg a day for six weeks followed by a reducing dose for two months in one and six months in the other) until both amiodarone and desethylamiodarone were undetectable. The radiographs, gallium lung scans, and lung function showed progressive improvement at follow up in two patients.
COMPARISON OF LUNG FUNCTION BETWEEN AMIODARONE AND CONTROL GROUPS
There was no difference between the amiodarone and the control groups for height, weight, mean systemic blood pressure, or cardiac functional class23 (table 2) . Patients in the amiodarone group were slightly younger than the controls. Mean values for maximal expiratory flow rates, static lung volumes, airways conductance, and TLCO were close to predicted values in both the amiodarone and the control group. Both groups had mild hypoxaemia at rest and an increased A-aDo, (table 2) .
There was no difference between the amiodarone and control groups in dynamic and static lung volume, specific airways conductance, TLCO, or helium single breath total lung capacity (VA). The amiodarone group had a slightly lower Kco (1 -67 (0-3) v 1-83 (0-3) mmol CO min' kPa-' 1-) (p < 0-04). The alveolararterial oxygen difference at maximal work load showed a similar fall from the values obtained at rest in the amiodarone and control groups (-1-6 (1-3) and -1-5 (1-0) kPa). The maximum tolerated work load was significantly lower in the amiodarone group than in the control group (120 (30) v 140 (25) w; p < 0-004). The differences between the two groups persisted when the three patients with presumed amiodarone pulmonary fibrosis were removed and the remaining 43 individuals were compared with 43 controls (Kco 1-72 (0-2) v 1-83 (0-3) mmol CO min-'kPa-'1 -'(p < 0-04); decrease in A-aDo, at maximal workload -1-7
(1 3) v -1-5(1 0) kPa; maximum workload 120 (30) v 138 (25) w; p < 0-004). Finally, there were no significant correlations between any lung function variable and cumulative dose of amiodarone (daily dose times days of treatment) when multiple regression analysis was carried out.
Amiodarone had to be withdrawn in 17 patients (32%) originally treated with the drug because it failed as an antiarrhythmic agent. The therapeutic efficacy (68%) is slightly lower than that reported from studies"5 11'2 with higher daily maintenance doses. Amiodarone was effective in controlling cardiac arrhythmias in the 61 patients in the present study.
Discussion
This study examined a population ofsymptomless patients followed by the same cardiologist in the outpatients clinic.'7 The prevalence of clinically evident pulmonary side effects was 49% (three cases), which is similar to that reported by Rotmensch et al (3-2%)2 in a multicentre follow up study in which a similar average daily dose of amiodarone had been given. A higher prevalence, ranging from 6% to 20%, has been reported in studies from the United States,58112 where higher doses of amiodarone are used (loading dose 1400 mg for two to three weeks followed by daily maintenance dose of 600-800 mg). Our daily maintenance dose of 400 mg provided amiodarone plasma concentrations above the therapeutic threshold (1 Mg/l) and, in general, below the toxic threshold of 2-5 Mg/1.25
In the present study two of the three patients with presumed pulmonary side effects showed mild to moderate clinical manifestations and the third had a subacute clinical onset. Radiographic and lung function data were in keeping with the diagnosis ofpneumonitis in all three patients and the diagnosis was supported by a positive gallium lung scan and an abnormal cell composition of the bronchoalveolar lavage fluid. 24 The abnormalities tended to resolve after amiodarone was withdrawn.
Pulmonary function tests showed moderate arterial hypoxaemia and an increase in the A-aDo2. This impairment in respiratory gas exchange at rest cannot be associated with amiodarone, however, because similar abnormalities occurred at rest and during exercise in the control group (table 2). The reduction in the A-aDo2 during exercise in both groups is consistent with ventilation-perfusion mismatching at rest that improves during exercise. This could be due to underlying coronary disease, despite the fact that the patients did not have functional limitations to suggest heart failure. Altematively, as many of these patients had smoked heavily, small airway dysfunction could contribute to these mild abnormalities of lung function.
Although the difference was statistically significant, the fact that patients taking amiodarone had a lower Kco than the control group is likely to be of limited clinical significance as it was a small difference. This finding and the lower work load achieved by the patients taking amiodarone might be due to a small but genuine effect of the drug at the doses used in the present study. The similar results for the A-aDo2 during exercise in the two groups suggests that the lower Kco in the patients having amiodarone does not explain the difference in maximum work load. The design ofthe exercise protocol cannot provide a clear explanation for the lower maximum work load observed in the amiodarone group (table  2) . It could be due to a direct cardiac effect of amiodarone. Both groups were studied about five years after the acute coronary episode, so the slightly longer time since myocardial infarction in the amiodarone group (table 2) is unlikely to account for the difference.
In summary, our patients receiving amiodarone for a year showed a low prevalence of lung function disturbances that is likely to be due to amiodarone. Lung function impairment compatible with amiodarone pneumonitis was observed in only three patients. Despite differences in study design, our results are consistent with a carefully conducted study done by Magro et al.'2 They showed that routine pulmonary function tests failed to predict amiodarone pulmonary side effects in asymptomatic patients, but were useful in patients with mild manifestations of the disease. They reported that a fall in TLCO of 15% or more in a patient with clinical suspicion of pulmonary toxicity gives a 100% sensitivity and an 89% specificity for the diagnosis of pulmonary complications of amiodarone treatment. Such figures could not be extrapolated to symptomless patients.12
A direct cytotoxic effect of amiodarone on the lung has been strongly supported by studies in animal models,26 clinical studies in patients,12
and epidemiological findings.5 The small differences in pulmonary function (Kco) between the amiodarone and the control group contrast with the large difference in thyroid function indices,20 which perhaps suggest a role for individual susceptibility in pulmonary complications of amiodarone treatment.
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